The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05894902
Recruitment Status : Not yet recruiting
First Posted : June 8, 2023
Last Update Posted : July 7, 2023
Sponsor:
Information provided by (Responsible Party):
Advanced Integrative Medical Science Institute

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Phase I safety and dose finding study of a standardized Ayahuasca analog (SM-001) in healthy adult volunteers

Condition or disease Intervention/treatment Phase
Major Depression Post Traumatic Stress Disorder Drug: SM-001 Phase 1

Detailed Description:

The Investigational New Drug SM-001 is formulated as a hot water decoction of two clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV). It represents a modern formulation of an ancient Amazonian botanical medicine, "ayahuasca" ("vine of the soul") that is used by many native South American indigenous and mestizo groups for both religious and medicinal purposes.

This initial Phase 1 study is to be conducted as an open label, dose-ranging safety assessment of a single dose of SM-001 taken orally by healthy adult volunteers. Twelve adult men and women, ages 25-65 years, will be consecutively assigned to one of three dose levels, 4 subjects per group (2 M; 2 F). In the presence of the Clinical Investigator(s), each subject will receive a single dose of SM-001, administered at the Clinical Study Site as a liquid at one of three dose levels: 0.25, 0.5, or1.5 ml SM-001 per kg body weight. To assess systemic exposure to SM-001, plasma levels of the four biomarkers, dimethyltryptamine, harmine, tetrahydroharmine, and harmaline will be measured. Blood samples will be drawn at baseline, HR 0 (pre-Study Drug dose), and then at HR 1, 2, 4, 8, and 24 post dose. Subjects will return to the Clinical Study Site at Study Day 28 for a final in-person assessment.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Subjects will be consecutively accrued to one of three study groups, starting at the lowest dose, Level 1 ("low" dose), and proceeding to the next higher dose level. Each subject will receive one dose of the Study Drug orally at the Clinical Study Site, according to their assigned dose Level. Dose levels vary by volume:

Level 1: 0.5 mL/kg ("low"; 50% of usual dose) N=4 (2M/2F) Level 2: 1 ml/kg ("medium"; 100% of usual dose) N=4 (2M/2F) Level 3: 2 ml/kg ("high"; 200% of usual dose) N=4 (2M/2F)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults
Estimated Study Start Date : October 1, 2023
Estimated Primary Completion Date : April 30, 2024
Estimated Study Completion Date : June 30, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Open label Phase I safety & dose finding study: low dose group
4 study participants will receive a low oral dose (0.5 mL/Kg) of SM-001
 Drug: SM-001
The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
Other Name: Ayahuasca
Active Comparator: Open label Phase I safety & dose finding study: medium dose group
4 study participants will receive a medium oral dose (1.0 mL/Kg) of SM-001
 Drug: SM-001
The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
Other Name: Ayahuasca
Active Comparator: Open label Phase I safety & dose finding study: high dose group
4 study participants will receive a high oral dose (2.0 mL/Kg) of SM-001
 Drug: SM-001
The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
Other Name: Ayahuasca


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Primary Objective [ Time Frame: 1-28 days ]

    To evaluate safety and tolerability of SM-001 in healthy adults following a single oral dose, at one of three different dose levels. The Incidence of Treatment-Emergent Adverse Events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE).

    Percentage of participants with at least one safety event [Time Frame: Baseline up to Day 28 ] Safety will be evaluated by the monitoring of adverse events (AEs), vital signs, blood pressure, heart rate, pulse oximetry, electrocardiogram (ECG) evaluations, clinical laboratory assessments and physical examination findings.



Secondary Outcome Measures :
  1. Short-term psychological impact [ Time Frame: 24 hours after single drug session ]
    To assess short-term psychological impact of a single dose of SM-001 at three different dose levels in healthy adults by asking each study subject to complete a questionnaire called the Hallucinogenic Rating Scale 24 hours after the single experimental drug session. This is an 85 item questionnaire with each item rated 0-4 with a maximum score of 340. A higher score correlates with a more intense psychological experience.

  2. Longer-term psychological impact [ Time Frame: Day 7 after a single drug session ]

    To assess longer-term psychological impact of a single dose of SM-001 at three different dose levels in healthy adults by asking each study subject to complete a questionnaire called the Persisting Effects Questionnaire 7 days following the single experimental drug session.

    The Persisting Effects Questionnaire includes 140 of the items that are rated on a 6-point scale (0=none, not at all; 1=so slight cannot decide; 2=slight; 3=moderate; 4=strong; 5=extreme, more than ever before in your life and stronger than 4).


  3. Bioavailability of SM-001 [ Time Frame: Day 1-2 ]
    To determine the blood, urine and feces levels of plant alkaloids including dimethyltryptamine, harmine, tetrahydroharmine and harmaline in ng/mL following a single oral dose of SM-001.

  4. Effects of a single dose of SM-001 on blood levels of brain derived nerve growth factor [ Time Frame: Day 1-28 ]
    Brain Derived Neurotrophic Factor will be quantitated (ng/mL) is each study subject's blood on the day before and the day after the SM-001 drug session.

  5. Effects of a single dose of SM-001 on blood cortisol blood levels [ Time Frame: Day 1 - 28 ]
    Cortisol levels in each study subject's blood will be measured (mg/mL)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adults: men and women ages 25-65 years of age
  • Previous experience with a psychedelic drug
  • Vital Signs within normal limits for temperature (oral), respiratory rate, heart rate
  • Normal blood pressure (for age) in the absence of antihypertensive drugs
  • Normal complete blood count and differential, platelets, coagulation ((PT/PTT)
  • Liver function tests ≤ 1.5X upper limits of normal
  • Renal function (BUN, serum Creatinine) - within normal limits
  • Able to understand and willing to comply with Study Protocol requirements.
  • Willing to abstain from alcohol for at least 72 hours prior to and following Study Day 0
  • No use of recreational drugs for at least 14 days prior to Study Day 0.
  • Women who are not pregnant or lactating.

Exclusion Criteria (None can apply):

  • Body Mass Index > 30 or < 20
  • Systemic condition that includes, but is not limited to: hematological, immunological, hepatic, renal, cardiac, neurological conditions that is under current treatment or causes abnormal physical or laboratory parameters.
  • History of seizures
  • History of drug or alcohol abuse
  • History of psychiatric disorder or history of significant trauma, as defined by DSM- V.
  • Use of SSRIs, MAO inhibitors, or other psychoactive compounds either pharmaceutical drugs or botanical in origin (i.e., 5-HTP, St John's Wort)
  • Any condition which, in the opinion of the Investigators, would preclude the use of the test article or the successful completion of the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05894902


Contacts
Layout table for location contacts
Contact: Leanna J Standish, ND PhD 2064201321 Lstandish@aimsinstitute.net
Contact: Sunil K Aggarwal, MD PhD 2064201321 saggarwal@aimsinstitute.net

Locations
Layout table for location information
United States, Washington
AIMS Institute
Seattle, Washington, United States, 98102
Contact: Michelle Speaks, MBA    206-420-1321    mspeaks@aimsinstitute.net   
Contact: Sunil K Aggarwal, MD, PhD    2064201321    saggarwal@aimsinstitute.net   
Principal Investigator: Leanna J Standish, ND PhD         
Sub-Investigator: Sunil K Aggarwal, MD, PhD         
Sponsors and Collaborators
Advanced Integrative Medical Science Institute
Investigators
Layout table for investigator information
Principal Investigator: Leanna J Standish, ND PhD AIMS Institute
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Advanced Integrative Medical Science Institute
ClinicalTrials.gov Identifier: NCT05894902    
Other Study ID Numbers: SM-001
First Posted: June 8, 2023    Key Record Dates
Last Update Posted: July 7, 2023
Last Verified: June 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Advanced Integrative Medical Science Institute:
Banisteriopsis caapi
Psychotria viridis
ayahuasca
ethnomedicine
 N,N-dimethyltryptamine (DMT)
harmine (HAR)
harmaline
tetrahydroharmine
Additional relevant MeSH terms:
Layout table for MeSH terms
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders
Mental Disorders